New AIDS Drugs Show Promise

ByABC News
July 10, 2000, 11:35 AM

D U R B A N, South Africa, July 10 -- The first of a newclass of AIDS drugs, known as fusion inhibitors, was welltolerated by patients when taken in combination with otherantiretrovirals in a 48-week study, researchers said today.

Data on T-20, which prevents HIV from entering cells ratherthan blocking its action once it arrives, were presented at the13th International AIDS Conference.

T-20, now in Phase II/III trials, is made by the U.S. biotechfirm Trimeris in partnership with Roche.

In the trial, 70 patients received twice daily subcutaneousinjections of T-20 in combination with other anti-HIV drugs.Prior to starting the trial, the patients had failed with an average of10 HIV/AIDS medications, and had advanced HIV disease.

Encouraging Data

After 48 weeks, 23 patients — or 56 percent of thosecompleting the 48 weeks of treatment — showed marked reductionsin the amount of HIV in their blood.

“We are happy to see the tolerability and antiviralactivity trends continue over the course of this year-longevaluation of T-20 combination regimens in these difficult totreat patients,” said Cal Cohen, director of the CommunityResearch Initiative of New England.

While the data are encouraging, further information fromongoing Phase III clinical studies is still needed toascertain the drug’s potential, researchers cautioned.

Fusion inhibitors, which work by stopping the HIV virus fromfusing with cell membranes, may offer hope to a growing numberof people with resistance to existing drugs.

One drawback is that T-20 has to be injected. But Roche saidit was hoping to overcome this problem in the years ahead via aresearch collaboration with Progenics Pharmaceuticals to create anoral version of the drug.

Sponsored Content by Taboola